0001615774-18-011317.txt : 20181025 0001615774-18-011317.hdr.sgml : 20181025 20181025160945 ACCESSION NUMBER: 0001615774-18-011317 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20181025 DATE AS OF CHANGE: 20181025 EFFECTIVENESS DATE: 20181025 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Tivorsan Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001705703 IRS NUMBER: 770702642 STATE OF INCORPORATION: DE FISCAL YEAR END: 1217 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-324385 FILM NUMBER: 181139001 BUSINESS ADDRESS: STREET 1: 3 DAVOL SQUARE, A301 CITY: PROVIDENCE STATE: RI ZIP: 02903 BUSINESS PHONE: 310-424-1986 MAIL ADDRESS: STREET 1: 2049 CENTURY PARK EAST, SUITE 320 CITY: LOS ANGELES STATE: CA ZIP: 90067 D 1 primary_doc.xml X0708 D LIVE 0001705703 Tivorsan Pharmaceuticals, Inc. 2049 CENTURY PARK EAST SUITE 320 LOS ANGELES CA CALIFORNIA 90067 310-424-1999 DELAWARE None None Corporation true Michael Meyers 2049 Century Park East Suite 320 Los Angeles CA CALIFORNIA 90067 Executive Officer John Nicholson 2049 Century Park East Suite 320 Los Angeles CA CALIFORNIA 90067 Director Commission above does not include 9,061 shares of common stock and warrants to purchase 36,250 shares of common stock with an exercise price of $1.60. Justin Fallon 2049 Century Park East Suite 320 Los Angeles CA CALIFORNIA 90067 Director Joel Braunstein 2049 Century Park East Suite 320 Los Angeles CA CALIFORNIA 90067 Director Jay Venkatesan 2049 Century Park East Suite 320 Los Angeles CA CALIFORNIA 90067 Director James Connolly 2049 Century Park East Suite 320 Los Angeles CA CALIFORNIA 90067 Director Pharmaceuticals Decline to Disclose 06b false 2016-01-29 false true true true false 5000 T.R. Winston & Company, LLC 10571 None None 2049 CENTURY PARK EAST SUITE 320 LOS ANGELES CA CALIFORNIA 90067 CA CALIFORNIA CT CONNECTICUT DE DELAWARE IL ILLINOIS MA MASSACHUSETTS NY NEW YORK PA PENNSYLVANIA RI RHODE ISLAND TX TEXAS false 2938000 2938000 0 false 35 14500 0 Commission above does not include 9,061 shares of common stock and warrants to purchase 36,250 shares of common stock with an exercise price of $1.60. 0 false Tivorsan Pharmaceuticals, Inc. /s/ Michael Meyers Michael Meyers Chief Executive Officer 2018-10-25